|
1
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Brenner H, Kloor M and Pox CP: Colorectal
cancer. Lancet. 383:1490–1502. 2014. View Article : Google Scholar
|
|
3
|
Guo P, Huang ZL, Yu P and Li K: Trends in
cancer mortality in China: an update. Ann Oncol. 23:2755–62. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Burotto M, Hartley ML, Marshall JL and
Pishvaian MJ: Future of targeted agents in metastatic colorectal
cancer. Colorectal Cancer. 5:433–443. 2012. View Article : Google Scholar
|
|
5
|
Wan D, He S, Xie B, et al: Aberrant
expression of miR-199a-3p and its clinical significance in
colorectal cancers. Med Oncol. 30:3782013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhou J, Li P, Xue X, et al: Salinomycin
induces apoptosis in cisplatin-resistant colorectal cancer cells by
accumulation of reactive oxygen species. Toxicol Lett. 222:139–145.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gale NW and Yancopoulos GD: Ephrins and
their receptors: a repulsive topic? Cell Tissue Res. 290:227–241.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kullander K and Klein R: Mechanisms and
functions of Eph and ephrin signalling. Nat Rev Mol Cell Biol.
3:475–486. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Murai KK and Pasquale EB: ‘Eph’ective
signaling: forward, reverse and crosstalk. J Cell Sci.
116:2823–2832. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Pasquale EB: The Eph family of receptors.
Curr Opin Cell Biol. 9:608–615. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zozulya SA and Udovichenko IP: Eph family
receptors as therapeutic targets. Bioorg Khim. 38:267–279. 2012.(In
Russian). PubMed/NCBI
|
|
12
|
Pasquale EB: Eph receptor signalling casts
a wide net on cell behaviour. Nat Rev Mol Cell Biol. 6:462–475.
2005. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Pasquale EB: Eph-ephrin bidirectional
signaling in physiology and disease. Cell. 133:38–52. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zisch AH and Pasquale EB: The Eph family:
a multitude of receptors that mediate cell recognition signals.
Cell Tissue Res. 290:217–226. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Heroult M, Schaffner F and Augustin HG:
Eph receptor and ephrin ligand-mediated interactions during
angiogenesis and tumor progression. Exp Cell Res. 312:642–650.
2006. View Article : Google Scholar
|
|
16
|
Cheng N, Brantley DM and Chen J: The
ephrins and Eph receptors in angiogenesis. Cytokine Growth Factor
Rev. 13:75–85. 2002. View Article : Google Scholar
|
|
17
|
Surawska H, Ma PC and Salgia R: The role
of ephrins and Eph receptors in cancer. Cytokine Growth Factor Rev.
15:419–433. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Vaught D, Brantley-Sieders DM and Chen J:
Eph receptors in breast cancer: roles in tumor promotion and tumor
suppression. Breast Cancer Res. 10:2172008. View Article : Google Scholar
|
|
19
|
Kinch MS and Carles-Kinch K:
Overexpression and functional alterations of the EphA2 tyrosine
kinase in cancer. Clin Exp Metastasis. 20:59–68. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kuijper S, Turner CJ and Adams RH:
Regulation of angiogenesis by Eph-ephrin interactions. Trends
Cardiovasc Med. 17:145–51. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Adams RH, Diella F, Hennig S, et al: The
cytoplasmic domain of the ligand ephrinB2 is required for vascular
morphogenesis but not cranial neural crest migration. Cell.
104:57–69. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sawamiphak S, Seidel S, Essmann CL, et al:
Ephrin-B2 regulates VEGFR2 function in developmental and tumour
angiogenesis. Nature. 465:487–491. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang Y, Nakayama M, Pitulescu ME, et al:
Ephrin-B2 controls VEGF-induced angiogenesis and lymphangiogenesis.
Nature. 465:483–486. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Foo SS, Turner CJ, Adams S, et al:
Ephrin-B2 controls cell motility and adhesion during
blood-vessel-wall assembly. Cell. 124:161–173. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Fire A, Xu S, Montgomery MK, et al: Potent
and specific genetic interference by double-stranded RNA in
Caenorhabditis elegans. Nature. 391:806–811. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Martinez J, Patkaniowska A, Urlaub H, et
al: Single-stranded antisense siRNAs guide target RNA cleavage in
RNAi. Cell. 110:563–574. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Shi Y: Mammalian RNAi for the masses.
Trends Genet. 19:9–12. 2003. View Article : Google Scholar
|
|
28
|
Grimm D and Kay MA: Therapeutic
application of RNAi: is mRNA targeting finally ready for prime
time? J Clin Invest. 117:3633–3641. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
McManus MT and Sharp PA: Gene silencing in
mammals by small interfering RNAs. Nat Rev Genet. 3:737–747. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Aagaard L and Rossi JJ: RNAi therapeutics:
principles, prospects and challenges. Adv Drug Deliv Rev. 59:75–86.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lee WR, Chung CL, Hsiao CJ, et al:
Suppression of matrix metalloproteinase-9 expression by
andrographolide in human monocytic THP-1 cells via inhibition of
NF-κB activation. Phytomedicine. 19:270–277. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Van Laar RK: An online gene expression
assay for determining adjuvant therapy eligibility in patients with
stage 2 or 3 colon cancer. Br J Cancer. 103:1852–1857. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
De Gramont A, de Gramont A, Chibaudel B,
et al: From chemotherapy to targeted therapy in adjuvant treatment
for stage III colon cancer. Semin Oncol. 38:521–532. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Dykxhoorn DM and Lieberman J: The silent
revolution: RNA interference as basic biology, research tool and
therapeutic. Annu Rev Med. 56:401–423. 2005. View Article : Google Scholar
|
|
35
|
Wu B, Hu K, Li S, et al:
Dihydroartiminisin inhibits the growth and metastasis of epithelial
ovarian cancer. Oncol Rep. 27:101–108. 2012.
|
|
36
|
Wu B, Li S, Sheng L, et al: Metformin
inhibits the development and metastasis of ovarian cancer. Oncol
Rep. 28:903–908. 2012.PubMed/NCBI
|
|
37
|
Nicosia RF and Ottinetti A: Growth of
microvessels in serum-free matrix culture of rat aorta. A
quantitative assay of angiogenesis in vitro. Lab Invest.
63:115–122. 1990.PubMed/NCBI
|
|
38
|
Djokovic D, Trindade A, Gigante J, et al:
Combination of Dll4/Notch and Ephrin-B2/EphB4 targeted therapy is
highly effective in disrupting tumor angiogenesis. BMC Cancer.
10:6412010. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Alam SM, Fujimoto J, Jahan I, et al:
Overexpression of ephrinB2 and EphB4 in tumor advancement of
uterine endometrial cancers. Ann Oncol. 18:485–490. 2007.
View Article : Google Scholar
|
|
40
|
Coulthard MG, Lickliter JD, Subanesan N,
et al: Characterization of the Epha1 receptor tyrosine kinase:
expression in epithelial tissues. Growth Factors. 18:303–317. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Boyd AW, Ward LD, Wicks IP, et al:
Isolation and characterization of a novel receptor-type protein
tyrosine kinase (hek) from a human pre-B cell line. J Biol Chem.
267:3262–3267. 1992.PubMed/NCBI
|
|
42
|
Tandon M, Vemula SV and Mittal SK:
Emerging strategies for EphA2 receptor targeting for cancer
therapeutics. Expert Opin Ther Targets. 15:31–51. 2011. View Article : Google Scholar :
|
|
43
|
Arvanitis D and Davy A: Eph/ephrin
signaling: networks. Genes Dev. 22:416–429. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Gale NW, Baluk P, Pan L, et al: Ephrin-B2
selectively marks arterial vessels and neovascularization sites in
the adult, with expression in both endothelial and smooth-muscle
cells. Dev Biol. 230:151–160. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Korff T, Braun J, Pfaff D, et al: Role of
ephrinB2 expression in endothelial cells during arteriogenesis:
impact on smooth muscle cell migration and monocyte recruitment.
Blood. 112:73–81. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Shin D, Garcia-Cardena G, Hayashi S, et
al: Expression of ephrinB2 identifies a stable genetic difference
between arterial and venous vascular smooth muscle as well as
endothelial cells and marks subsets of microvessels at sites of
adult neovascularization. Dev Biol. 230:139–150. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Salvucci O, Maric D, Economopoulou M, et
al: EphrinB reverse signaling contributes to endothelial and mural
cell assembly into vascular structures. Blood. 114:1707–1716. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Bentley K, Mariggi G, Gerhardt H and Bates
PA: Tipping the balance: robustness of tip cell selection,
migration and fusion in angiogenesis. PLoS Comput Biol.
5:e10005492009. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Xia G, Kumar SR, Masood R, et al: EphB4
expression and biological significance in prostate cancer. Cancer
Res. 65:4623–4632. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Alam SM, Fujimoto J, Jahan I, et al:
Coexpression of EphB4 and ephrinB2 in tumour advancement of ovarian
cancers. Br J Cancer. 98:845–851. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Brantley-Sieders DM: Clinical relevance of
Ephs and ephrins in cancer: lessons from breast, colorectal and
lung cancer profiling. Semin Cell Dev Biol. 23:102–108. 2012.
View Article : Google Scholar :
|
|
52
|
Yancopoulos GD, Davis S, Gale NW, et al:
Vascular-specific growth factors and blood vessel formation.
Nature. 407:242–248. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Sun B, Zhang D, Zhang S, et al: Hypoxia
influences vasculogenic mimicry channel formation and tumor
invasion-related protein expression in melanoma. Cancer Lett.
249:188–197. 2007. View Article : Google Scholar
|
|
54
|
Cao Y: Tumor angiogenesis and therapy.
Biomed Pharmacother. 59:S340–S343. 2005. View Article : Google Scholar
|
|
55
|
Mahabeleshwar GH and Byzova TV:
Angiogenesis in melanoma. Semin Oncol. 34:555–565. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Kerbel RS: Tumor angiogenesis. N Engl J
Med. 358:2039–2049. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Nyberg P, Salo T and Kalluri R: Tumor
microenvironment and angiogenesis. Front Biosci. 13:6537–6553.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Perez-Gomez E, Del Castillo G, Juan
Francisco S, et al: The role of the TGF-β coreceptor endoglin in
cancer. Sci World J. 10:2367–2384. 2010. View Article : Google Scholar
|
|
59
|
Medetoglu B, Gunluoglu MZ, Demir A, et al:
Tumor angiogenesis in predicting the survival of patients with
stage I lung cancer. J Thorac Cardiovasc Surg. 140:996–1000. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Kiselyov A, Balakin KV and Tkachenko SE:
VEGF/VEGFR signalling as a target for inhibiting angiogenesis.
Expert Opin Investig Drugs. 16:83–107. 2007. View Article : Google Scholar
|
|
61
|
Kubota Y: Tumor angiogenesis and
anti-angiogenic therapy. Keio J Med. 61:47–56. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Bergers G, Brekken R, McMahon G, et al:
Matrix metalloproteinase-9 triggers the angiogenic switch during
carcinogenesis. Nat Cell Biol. 2:737–744. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Bellon G, Martiny L and Robinet A: Matrix
metalloproteinases and matrikines in angiogenesis. Crit Rev Oncol
Hematol. 49:203–220. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Velinov N, Poptodorov G, Gabrovski N and
Gabrovksi S: The role of matrix metalloproteinases in the tumor
growth and metastasis. Khirurgiia (Sofiia). 1:44–49. 2010.(In
Bulgarian).
|
|
65
|
Groblewska M, Siewko M, Mroczko B and
Szmitkowski M: The role of matrix metalloproteinases (MMPs) and
their inhibitors (TIMPs) in the development of esophageal cancer.
Folia Histochem Cytobiol. 50:12–19. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Deryugina EI and Quigley JP: Matrix
metalloproteinases and tumor metastasis. Cancer Metastasis Rev.
25:9–34. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Kim TD, Song KS, Li G, et al: Activity and
expression of urokinase-type plasminogen activator and matrix
metalloproteinases in human colorectal cancer. BMC Cancer.
6:2112006. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Lukaszewicz-Zajac M, Mroczko B and
Szmitkowski M: Gastric cancer - The role of matrix
metalloproteinases in tumor progression. Clin Chim Acta.
412:1725–1730. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Grishok A, Tabara H and Mello CC: Genetic
requirements for inheritance of RNAi in C. elegans. Science.
287:2494–2497. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Harborth J, Elbashir SM, Bechert K, et al:
Identification of essential genes in cultured mammalian cells using
small interfering RNAs. J Cell Sci. 114:4557–4565. 2001.
|
|
71
|
Yu JY, DeRuiter SL and Turner DL: RNA
interference by expression of short-interfering RNAs and hairpin
RNAs in mammalian cells. Proc Natl Acad Sci USA. 99:6047–6052.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Yang X, Zhang Y, Zhang L, et al: Silencing
alpha-fetoprotein expression induces growth arrest and apoptosis in
human hepatocellular cancer cell. Cancer Lett. 271:281–293. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Chai H and Yang Y: Effects of MACC1 siRNA
on biological behaviors of HeLa. Arch Gynecol Obstet.
289:1271–1280. 2014. View Article : Google Scholar
|
|
74
|
Lui Z, Ma Q, Wang X and Zhang Y:
Inhibiting tumor growth of colorectal cancer by blocking the
expression of vascular endothelial growth factor receptor 3 using
interference vector-based RNA interference. Int J Mol Med.
25:59–64. 2010.
|
